Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options.
Members of Portola’s management team, working together or individually, have played central roles at prior companies in discovering, developing and commercializing a number of successful therapeutics in the area of thrombosis, including Integrilin® and Xarelto®.
Portola’s development pipeline includes three wholly-owned* and one partnered program. In thrombosis, Portola has initiated a pivotal Phase 3 study of its lead molecule, betrixaban, a novel, oral once-daily inhibitor of Factor Xa. For PRT4445, a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery, Portola initiated a series of Phase 2 proof-of-concept studies in healthy volunteers in December 2012. Assuming success of the Phase 2 proof-of-concept studies, Portola intends to work with the FDA to design and implement a registration program for PRT4445, which the company anticipates initiating in 2014.
In hematologic disorders and inflammation, Portola is developing PRT2070, an orally available kinase inhibitor that inhibits spleen tyrosine kinase (Syk) and janus kinases (JAK), enzymes that regulate important signaling pathways. Subject to regulatory approval, Portola plans to initiate a Phase 1/2 clinical study of PRT2070 in 2013 in patients with B-cell hematologic cancers who have failed or relapsed on existing marketed therapies or products in development, including patients with identified mutations.
PRT2607 and other highly selective Syk inhibitors are partnered with Biogen Idec Inc.
*PRT2070 Worldwide Commercial Rights: Hematologic cancer and other systemic indications wholly owned by Portola. Certain nonsystemic indications are shared 50/50 rights with Aciex.